Related references
Note: Only part of the references are listed.Inhibition of histone H3K27 demethylases selectively modulates inflammatory phenotypes of natural killer cells
Adam Cribbs et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2018)
BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines
Delphine Merino et al.
CANCER CELL (2018)
CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014
Quinn T. Ostrom et al.
NEURO-ONCOLOGY (2017)
Chaetocin induces cell cycle arrest and apoptosis by regulating the ROS-mediated ASK-1/JNK signaling pathways
Jingliang He et al.
ONCOLOGY REPORTS (2017)
KDM2B, an H3K36-specific demethylase, regulates apoptotic response of GBM cells to TRAIL
Ibrahim Cagri Kurt et al.
CELL DEATH & DISEASE (2017)
Identification of Mitoxantrone as a TRAIL-sensitizing agent for Glioblastoma Multiforme
Filiz Senbabaoglu et al.
CANCER BIOLOGY & THERAPY (2016)
Discovery and characterization of Isofistularin-3, a marine brominated alkaloid, as a new DNA demethylating agent inducing cell cycle arrest and sensitization to TRAIL in cancer cells
Cristina Florean et al.
ONCOTARGET (2016)
Hallmarks of glioblastoma: a systematic review
Dorte Schou Noroxe et al.
ESMO OPEN (2016)
Chaetocin induces endoplasmic reticulum stress response and leads to death receptor 5-dependent apoptosis in human non-small cell lung cancer cells
Xianfang Liu et al.
APOPTOSIS (2015)
Upregulation of Death Receptor 5 and Production of Reactive Oxygen Species Mediate Sensitization of PC-3 Prostate Cancer Cells to TRAIL Induced Apoptosis by Vitisin A
Deokil Shin et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2015)
TRAIL-Based High Throughput Screening Reveals a Link between TRAIL-Mediated Apoptosis and Glutathione Reductase, a Key Component of Oxidative Stress Response
Dmitri Rozanov et al.
PLOS ONE (2015)
The SUV39H1 inhibitor chaetocin induces differentiation and shows synergistic cytotoxicity with other epigenetic drugs in acute myeloid leukemia cells
Y-S Lai et al.
BLOOD CANCER JOURNAL (2015)
CCTop: An Intuitive, Flexible and Reliable CRISPR/Cas9 Target Prediction Tool
Manuel Stemmer et al.
PLOS ONE (2015)
sROS-dependent activation of JNK converts p53 into an efficient inhibitor of oncogenes leading to robust apoptosis
Y. Shi et al.
CELL DEATH AND DIFFERENTIATION (2014)
Histone deacetylase inhibitors and cell death
Jing Zhang et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2014)
Improved vectors and genome-wide libraries for CRISPR screening
Neville E. Sanjana et al.
NATURE METHODS (2014)
Chaetocin-induced ROS-mediated apoptosis involves ATM-YAP1 axis and JNK-dependent inhibition of glucose metabolism
D. Dixit et al.
CELL DEATH & DISEASE (2014)
TRAIL combinations: The new 'trail' for cancer therapy
Alaa Refaat et al.
ONCOLOGY LETTERS (2014)
Chaetocin antileukemia activity against chronic myelogenous leukemia cells is potentiated by bone marrow stromal factors and overcomes innate imatinib resistance
L. Truitt et al.
ONCOGENESIS (2014)
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Michael I. Love et al.
GENOME BIOLOGY (2014)
Improved Therapeutic Effect against Leukemia by a Combination of the Histone Methyltransferase Inhibitor Chaetocin and the Histone Deacetylase Inhibitor Trichostatin A
Huong Thi Thanh Tran et al.
JOURNAL OF KOREAN MEDICAL SCIENCE (2013)
Chaetocin is a nonspecific inhibitor of histone lysine methyltransferases
Fanny L. Cherblanc et al.
NATURE CHEMICAL BIOLOGY (2013)
Structure-guided design of a selective BCL-XL inhibitor
Guillaume Lessene et al.
NATURE CHEMICAL BIOLOGY (2013)
Real-time imaging of the dynamics of death receptors and therapeutics that overcome TRAIL resistance in tumors
T. Bagci-Onder et al.
ONCOGENE (2013)
Identification of 5-Iodotubercidin as a Genotoxic Drug with Anti-Cancer Potential
Xin Zhang et al.
PLOS ONE (2013)
SAHA/TRAIL combination induces detachment and anoikis of MDA-MB231 and MCF-7 breast cancer cells
M. Lauricella et al.
BIOCHIMIE (2012)
The anticancer effects of chaetocin are independent of programmed cell death and hypoxia, and are associated with inhibition of endothelial cell proliferation
C. R. Isham et al.
BRITISH JOURNAL OF CANCER (2012)
ROS-independent JNK activation and multisite phosphorylation of Bcl-2 link diallyl tetrasulfide-induced mitotic arrest to apoptosis
Mareike Kelkel et al.
CARCINOGENESIS (2012)
Anti-leukemia activity of chaetocin via death receptor-dependent apoptosis and dual modulation of the histone methyl-transferase SUV39H1
H. Chaib et al.
LEUKEMIA (2012)
Chromatin-modifying enzymes as modulators of reprogramming
Tamer T. Onder et al.
NATURE (2012)
Antitumor activity of a small-molecule inhibitor of the histone kinase Haspin
D. Huertas et al.
ONCOGENE (2012)
Histone deacetylase inhibitors sensitize glioblastoma cells to TRAIL-induced apoptosis by c-myc-mediated downregulation of cFLIP
A. Bangert et al.
ONCOGENE (2012)
NRF2 and cancer: the good, the bad and the importance of context
Michael B. Sporn et al.
NATURE REVIEWS CANCER (2012)
Current Concepts and Management of Glioblastoma
Matthias Preusser et al.
ANNALS OF NEUROLOGY (2011)
A Dual PI3K/mTOR Inhibitor, PI-103, Cooperates with Stem Cell-Delivered TRAIL in Experimental Glioma Models
Tugba Bagci-Onder et al.
CANCER RESEARCH (2011)
Combined inhibition of DNA methyltransferase and histone deacetylase restores caspase-8 expression and sensitizes SCLC cells to TRAIL
Vitaliy O. Kaminskyy et al.
CARCINOGENESIS (2011)
Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase
Christian Frezza et al.
NATURE (2011)
Loss of Thioredoxin Reductase 1 Renders Tumors Highly Susceptible to Pharmacologic Glutathione Deprivation
Pankaj Kumar Mandal et al.
CANCER RESEARCH (2010)
DNMT1 and DNMT3b silencing sensitizes human hepatoma cells to TRAIL-mediated apoptosis via up-regulation of TRAIL-R2/DR5 and caspase-8
Satoshi Kurita et al.
CANCER SCIENCE (2010)
The BCL-2 Family Reunion
Jerry E. Chipuk et al.
MOLECULAR CELL (2010)
The Anticancer Agent Chaetocin Is a Competitive Substrate and Inhibitor of Thioredoxin Reductase
Jennifer D. Tibodeau et al.
ANTIOXIDANTS & REDOX SIGNALING (2009)
A Novel Experimental Heme Oxygenase-1-Targeted Therapy for Hormone-Refractory Prostate Cancer
Moulay A. Alaoui-Jamali et al.
CANCER RESEARCH (2009)
Blinded by the Light: The Growing Complexity of p53
Karen H. Vousden et al.
CELL (2009)
ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor
Christin Tse et al.
CANCER RESEARCH (2008)
Baicalein Overcomes Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Resistance via Two Different Cell-Specific Pathways in Cancer Cells but not in Normal Cells
Hiroya Taniguchi et al.
CANCER RESEARCH (2008)
Inhibition of heme oxygenase 1 expression by small interfering RNA decreases orthotopic tumor growth in livers of mice
Gabriele Sass et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Valproic acid induces apoptosis in chronic lymphocytic leukemia cells through activation of the death receptor pathway and potentiates TRAIL response
Laurence Lagneaux et al.
EXPERIMENTAL HEMATOLOGY (2007)
Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis
Ronald Koschny et al.
CLINICAL CANCER RESEARCH (2007)
Chaetocin: a promising new antimyeloma agent with in vitro and in vivo activity mediated via imposition of oxidative stress
Crescent R. Isham et al.
BLOOD (2007)
TRAIL signalling: Decisions between life and death
Christina Falschlehner et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2007)
5-aza-2′-deoxycytidine and IFN-γ cooperate to sensitize for TRAIL-induced apoptosis by upregulating caspase-8
S. Fulda et al.
ONCOGENE (2006)
The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL
Lisa M. Butler et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
RNAi Codex: a portal/database for short-hairpin RNA (shRNA) gene-silencing constructs
A. Olson et al.
NUCLEIC ACIDS RESEARCH (2006)
Identification of a specific inhibitor of the histone methyltransferase SU(VAR)3-9
D Greiner et al.
NATURE CHEMICAL BIOLOGY (2005)
Depsipeptide (FR901228) enhances the cytotoxic activity of TRAIL by redistributing TRAIL receptor to membrane lipid rafts
RL VanOosten et al.
MOLECULAR THERAPY (2005)
Cotreatment with histone deacetylase inhibitor LAQ824 enhances apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells
F Guo et al.
CANCER RESEARCH (2004)
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2
LT Vassilev et al.
SCIENCE (2004)
CHOP is involved in endoplasmic reticulum stress-induced apoptosis by enhancing DR5 expression in human carcinoma cells
H Yamaguchi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
The histone deacetylase inhibitor suberic bishydroxamate: a potential sensitizer of melanoma to TNF-related apoptosis-inducing ligand (TRAIL) induced apoptosis
XD Zhang et al.
BIOCHEMICAL PHARMACOLOGY (2003)
PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes
VK Mootha et al.
NATURE GENETICS (2003)
Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia
M MacFarlane et al.
ONCOGENE (2002)
Analysis of FasL and TRAIL induced apoptosis pathways in glioma cells
MJ Knight et al.
ONCOGENE (2001)
Resistance to TRAIL-induced apoptosis in primitive neuroectodermal brain tumor cells correlates with a loss of caspase-8 expression
MA Grotzer et al.
ONCOGENE (2000)
Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition
CY Du et al.
CELL (2000)